JYJian-Ying Mbbs Yang

Jian-Ying Mbbs Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian-Ying Mbbs Yang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in primary Sjögren’s disease: prognostic impact on mortality and cancer

    by Chunxin Lei, Xiya Zhang, Yan Zhang, Yunlong Fang, Jiaqi Chen, Zihan Liu, Xuanyi Zhou, Bojie Tang, Jiahe Liao, Ziwei Huang, et al.

    Objective: To assess the impact of sex on mortality and malignancy in patients with primary Sjögren’s disease (pSD). Methods: This ambispective cohort study included 1,182 pSD patients (1,025 women and 157 men) from the China–Japan Friendship Hospital between 2014–2023 and followed through 2024. Survival outcomes were estimated via Kaplan–Meier curves, and SMRs were calculated. Independent risk factors were identified via multivariate Cox regression, followed by stepwise Cox, sex-stratified and interaction analyses. Results: During follow-up, 125 deaths (10.6%) and 33 malignancies (2.8%) occurred, both of which were more common in men (log–rank tests, P < 0.001). Overall mortality was markedly higher in men (25.5%, SMR = 4.79) than in women (8.3%, SMR = 2.42). Male sex was independently associated with higher risk of mortality (HR = 1.998, P = 0.004) and cancer incidence (HR = 3.799, P = 0.001). Sex-stratified analyses revealed distinct death–associated factors: interstitial lung disease (ILD), pulmonary infection and ischemic stroke were independently associated with mortality in men, whereas older age, low C3, elevated C-reactive protein and total bilirubin (TBIL) levels were associated with mortality in women. With respect to cancer, longer disease duration, lymphadenopathy, lymphocytopenia, elevated TBIL and hypochloremia were independently associated with cancer risk in women, whereas no variables showed an independent association with cancer risk among men. Interaction analyses demonstrated additive interactions between male sex and elevated ESSDAI scores, as well as male sex and concomitant ILD, in relation to mortality. Conclusion: Compared with women, men with pSD presented greater risks and distinct risk profiles of death and malignancy. Moreover, male sex was independently associated with adverse outcomes and acted as an important effect modifier, highlighting the need for sex-specific risk stratification and clinical management. Trial registration: This ambispective cohort study was registered in the Clinical Trial Registry (ID: NCT06528197) on June 27, 2024 and conducted in accordance with the Declaration of Helsinki.


  • Open Access

    Time-Dependent Mortality Predictors in Primary Sjögren’s Syndrome: C-Reactive Protein for Early Risk and Age for Late Outcomes

    by Jia-Qi Chen, Yan Zhang, Zi-Wei Huang, Jian-Ying Yang, Jia-He Liao, Chun-Xin Lei, Xi-Ya Zhang, Xin-Bo Yu, Tzu-Hua Wu, Zi-Han Liu, et al.

    Purpose: To identify risk factors for near-term and long-term death in patients with primary Sjogren’s syndrome (pSS). Patients and Methods: This ambispective cohort study included all patients with pSS treated at China–Japan Friendship Hospital between 2013 and 2023. The time-dependent Cox regression analysis was used for statistical analysis of risk factors, with 3 months and 60 months as the cut-off time points and all-cause death as the primary endpoint. Results: Among the 1252 included patients, 138 patients had died by the end of follow-up (11.0%). Age at diagnosis, C-reactive protein (CRP) levels and total bilirubin (TBIL) were time-dependent risk factors for mortality. Within 3 months of follow-up, age > 65 years had no effect on mortality, but after 3 months of follow-up, the mortality risk in patients aged > 65 years increased over time (HR 3.97, 95% CI 2.57– 6.13; HR 16.63, 95% CI 5.53– 50.03). CRP > 6.5 mg/L increased the risk of mortality within 3 months (HR=11.45, 95% CI 2.52– 51.95), followed by 3– 60 months (HR=2.94, 95% CI 1.94– 4.45), but did not affect survival after 60 months of follow-up. TBIL > 18.01 μmol/L increased the risk of mortality in pSS patients within 3– 6 months (HR=2.30, 95% CI 1.42– 3.79) but did not increase the risk of mortality in patients with pSS within 3 months of follow-up or after 60 months. Conclusion: pSS patients with a CRP level > 6.5 mg/L have an 11-fold increased risk of near-term death, whereas pSS patients older than 65 years of age at diagnosis have a 16-fold increased risk of long-term death.


  • Open Access

    Disease Duration Affects the Clinical Phenotype of Primary Sjögren Syndrome

    by Yan Mbbs Zhang, Jian-Ying Mbbs Yang, Jia-Qi Mmed Chen, Jia-He Mmed Liao, Zi-Wei Mmed Huang, Tzu-Hua Mmed Wu, Qian Mmed He, Xin-Bo Mmed Yu, Qin Mbbs Wang, Wei-Jiang Song, et al.

    Objectives: To investigate the impact of disease duration on clinical phenotypes in Chinese patients with primary Sjögren syndrome (pSS) and examine the correlation between clinical phenotypes and onset age, age at diagnosis, and disease duration. Methods: Data from 952 patients diagnosed with pSS in China between January 2013 and March 2022 were analyzed based on medical records. Patients were categorized into 3 groups based on disease duration: short (p p p p p p < 0.05), anti-Ro52 (p < 0.05), and anti-SSB (p < 0.05) positivity than their control groups, with prevalence increasing with disease duration (p trend < 0.001). However, no differences were noted in the prevalence of interstitial lung disease and leukopenia between different disease duration groups after matching for age at onset, although differences were shown when matching for age at diagnosis. Conclusion: Longer disease duration in pSS patients correlates with increased prevalence of sicca symptoms, fatigue, and arthralgia and higher positivity of autoantibodies associated with pSS. However, the prevalence of interstitial lung disease and leukopenia did not correlate with disease duration after matching for age at onset.


  • Open Access

    Sex Difference in Primary Sjögren Syndrome

    by Yan Mbbs Zhang, Jia-Qi Mbbs Chen, Jian-Ying Mbbs Yang, Jia-He Mmed Liao, Tzu-Hua Mmed Wu, Xin-Bo Mbbs Yu, Zi-Wei Mmed Huang, Qian Mmed He, Qin Mbbs Wang, Wei-Jiang Song, et al.

    Objectives: The aim of this study was to study clinical and biological differences between men and women with primary Sjögren syndrome (pSS) in China and perform a literature review to confirm if the clinical phenotypes are affected by sex in patients with pSS. Methods: Data from 961 patients with pSS treated at a tertiary hospital in China between January 2013 and March 2022 were analyzed based on medical records. Clinical characteristics, including disease manifestations and serological parameters of the disease, were compared between men and women with pSS using the Mann-Whitney U test and χ2 test. Results: This study included 140 (14.6%) men and 821 (85.4%) women with pSS. Women with pSS demonstrated a higher prevalence of dry mouth, dry eyes, arthralgia, and dental caries (p < 0.05); higher erythrocyte sedimentation rate and immunoglobulin M levels (p < 0.05); higher prevalence of leukopenia, neutropenia, anemia, low complement 3, and low complement 4 (p < 0.05); and higher titers of antinuclear antibody, anti-Sjögren syndrome A, anti-Ro52, and rheumatoid factor positivity (p < 0.05) than men, whereas men with pSS had a higher prevalence of parotid enlargement and interstitial lung disease (p < 0.05). Conclusions: Women with pSS are associated with more dryness, cytopenia, hypocomplementemia, and autoantibody positivity. Although men with pSS probably have lighter sicca symptoms and lower immunoactivity and serologic responses, regular monitoring of interstitial lung disease in men is vital.


  • Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study

    by Qian He, Jia-Qi Chen, Xin-Bo Yu, Jia-He Liao, Zi-Wei Huang, Jian-Ying Yang, Tzu-Hua Wu, Wei-Jiang Song, Jing Luo, Qing-Wen Tao

    Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been applied for treating axial spondyloarthritis (axSpA). However, there is a glaring absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were used to analyze and visualize the quantity and citations of publications, as well as to identify “research hotspots” and trends in this field. BibExcel version 1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA were included in this bibliometric analysis. Overall, the number of publications has been increasing steadily annually. The USA (23.21%, 591 publications) ranked first with the largest output of papers, followed by Germany, and the Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher (119 articles). Annals of the Rheumatic Diseases published the most documents (6.76%, 172 publications) in this field. The predominant hotspots have been “tuberculosis,” “IL-17,” and “quality of life” in the field until 2020. Since 2015, “biosimilar pharmaceuticals” has retained the popularity. Current research hotspots are “spinal radiographic progression,” Janus kinase (JAK) inhibitors, and adverse events (AEs). Machine learning has become popular gradually. Globally, there has been a steady increase in the number of studies on bDMARDs use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar pharmaceuticals, and AEs are current research hotspots. Machine learning is emerging research hotspots and trends in this field.


  • Research on primary Sjögren’s syndrome in 2004–2021: a Web of Science-based cross-sectional bibliometric analysis

    by Jiaqi Chen, Qian He, Bohan Jiang, Weijiang Song, Zihua Wu, Jianying Yang, Ziwei Huang, Xinbo Yu, Jing Luo, Qingwen Tao

    The extent, range, and nature of available research in the field of primary Sjögren’s syndrome (pSS) have not been understood fully. This study aimed to map the literature available on pSS, and identify global hotspots and trends in the research. Papers on pSS published between 2004 and 2021 were searched from Web of Science Core Collection. The quantity and citations of publications, and the research hotspots and trends in the field of pSS were analyzed and presented visually by Microsoft Excel and Citespace software. A total of 3606 papers mainly from 526 institutions in 83 countries/regions were included for analysis. The number of publications presented an overall upward trend in the field of pSS from 2004 to 2021. The USA ranked first in the number of publications (n = 661), followed by China (n = 491), Italy (n = 405), France (n = 351), and Japan (n = 292). Moreover, seven of the top ten countries by the number of publications on pSS were from Europe. The University of Groningen (n = 661), Xavier Mariette (n = 95), and Clinical and Experimental Rheumatology (n = 184) were the most prolific affiliation, author, and journal, respectively. Vitali C (n = 2009) and Arthritis and Rheumatism (n = 3918) held the record for the most cited papers by an author and journal, respectively. At present, the hot keywords in the field of pSS include disease activity, ultrasonography, management, consensus, and data-driven. Lymphoid organization, clinical phenotypes outcome, salivary gland ultrasonography, and Toll-like receptor are the emerging research trends in pSS. Research on pSS is flourishing. Current research of pSS mainly focuses on disease activity, ultrasonography, and management. While, the emerging research trends in pSS are lymphoid organization, clinical phenotypes outcome, salivary gland ultrasonography, and Toll-like receptor.